Antigen-targeted immune cell treatment for high-risk ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This early-phase trial tests a lab-made immune cell treatment designed to recognize ovarian cancer and attack it. It may help people with high-risk ovarian cancer who still need effective options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) are age 10 or older and can give informed consent (or have a guardian do so).
- Your cancer is high-risk ovarian cancer that has been confirmed on biopsy/surgery and is Stage II to IV.
- Your general condition is good enough (ECOG 0–1) and you’re expected to live at least 12 weeks.
- Your blood counts and organ function are strong enough (enough neutrophils and platelets; acceptable liver and kidney tests).
- You are not pregnant and will use appropriate birth control, if you could become pregnant.
- You test negative for HIV and hepatitis C (and screening doesn’t show active TB or certain other infections).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether giving your own immune cells—engineered to target the FSH receptor—can control recurrent ovarian-related cancers. It’s mainly looking at safety and early signs of activity for patients whose cancer has not responded well to standard platinum chemotherapy.
This trial tests a new combination of treatments for advanced ovarian, fallopian tube, or peritoneal cancer. It combines chemotherapy and immunotherapy (drugs that help your immune system fight cancer) with a special vaccine made from your own tumor. The goal is to see if this approach is more effective than standard treatment.
This study tests an experimental therapy called SCT-001 CAR T cells, made from your own immune cells, for ovarian cancer that has not responded to standard treatments. The goal is to see if these engineered cells can find and attack your cancer cells, which could help shrink or control the disease.
This trial tests a personalized treatment using your own immune cells (called TILs) to fight ovarian cancer that has returned. After collecting and growing these cells, you receive chemotherapy and other drugs to help them work better.
This study tests two new experimental drugs (XmAb541 and XmAb808) designed to fight advanced ovarian cancer by activating your immune system. You'll be closely monitored to see how safe the drugs are and how your body tolerates them.
This trial tests a personalized vaccine made from your tumor's genetic material. It is given after surgery to help your immune system recognize and attack any remaining cancer cells, with the goal of preventing the cancer from coming back.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.